Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
- PMID: 23834666
- DOI: 10.1111/hae.12228
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B
Abstract
BAX326 is a recombinant factor IX (rFIX; nonacog gamma) manufactured without the addition of any materials of human or animal origin, and with two viral inactivation steps (solvent/detergent treatment and 15 nm nanofiltration). The aim of this prospective trial was to investigate the pharmacokinetics, haemostatic efficacy and safety of BAX326 in previously treated patients aged 12-65 years with severe or moderately severe haemophilia B. BAX326 was safe and well tolerated in all 73 treated subjects; adverse events considered related to treatment (2.7% incidence, all non-serious) were transient and mild, and no hypersensitivity reactions, inhibitor formation or thrombotic events were observed. Pharmacokinetic (PK) equivalence (n = 28) between BAX326 and a licensed rFIX was confirmed in terms of the ratio of geometric mean AUC(0-72) h per dose. Twice-weekly prophylaxis [mean duration 6.2 (±0.7) months; 1.8 (±0.1) infusions per week, 49.5 (±4.8) IU kg(-1) per infusion] was effective in preventing bleeding episodes, with a significantly lower (79%, P < 0.001) annualized bleed rate (4.2) compared to an on-demand treatment in a historical control group (20.0); 24 of 56 subjects on prophylaxis (43%) did not bleed throughout the study observation period. Of 249 total acute bleeds, 211 (84.7%) were controlled with one to two infusions of BAX326. Haemostatic efficacy at resolution of bleed was rated excellent or good in 96.0% of all treated bleeding episodes. The results of this study indicate that BAX326 is safe and efficacious in treating bleeds and routine prophylaxis in patients aged 12 years and older with haemophilia B.
Keywords: BAX326; haemophilia B; previously treated patients; recombinant factor IX.
© 2013 John Wiley & Sons Ltd.
Similar articles
-
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.Haemophilia. 2014 Sep;20(5):651-8. doi: 10.1111/hae.12419. Epub 2014 Apr 3. Haemophilia. 2014. PMID: 24697870 Clinical Trial.
-
Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).Haemophilia. 2014 Sep;20(5):674-81. doi: 10.1111/hae.12444. Epub 2014 Apr 10. Haemophilia. 2014. PMID: 24720694 Clinical Trial.
-
Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.Haemophilia. 2015 Mar;21(2):196-203. doi: 10.1111/hae.12548. Epub 2014 Dec 11. Haemophilia. 2015. PMID: 25495591 Clinical Trial.
-
BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B.Ther Adv Hematol. 2014 Oct;5(5):168-80. doi: 10.1177/2040620714550573. Ther Adv Hematol. 2014. PMID: 25324957 Free PMC article. Review.
-
Clinical evaluation of recombinant factor IX.Semin Hematol. 1998 Apr;35(2 Suppl 2):33-8. Semin Hematol. 1998. PMID: 9565165 Review.
Cited by
-
A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B.J Blood Med. 2024 Mar 5;15:113-122. doi: 10.2147/JBM.S425617. eCollection 2024. J Blood Med. 2024. PMID: 38481741 Free PMC article.
-
Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B.Glob Reg Health Technol Assess. 2020 Jul 14;7:40-49. doi: 10.33393/grhta.2020.2113. eCollection 2020 Jan-Dec. Glob Reg Health Technol Assess. 2020. PMID: 36627960 Free PMC article.
-
International consensus recommendations on the management of people with haemophilia B.Ther Adv Hematol. 2022 Apr 2;13:20406207221085202. doi: 10.1177/20406207221085202. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35392437 Free PMC article. Review.
-
IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data.J Clin Med. 2022 Feb 18;11(4):1071. doi: 10.3390/jcm11041071. J Clin Med. 2022. PMID: 35207344 Free PMC article. Review.
-
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.Cochrane Database Syst Rev. 2021 Aug 18;8(8):CD014201. doi: 10.1002/14651858.CD014201. Cochrane Database Syst Rev. 2021. PMID: 34407214 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources